

Preventive Aspects of Coronary Heart Disease

Preventive Aspects of Coronary Heart Disease

Edward D. Frohlich, M.D. / Editor

Alton Ochsner Distinguished Scientist
Vice President for Academic Affairs
Alton Ochsner Medical Foundation
New Orleans, Louisiana

CARDIOVASCULAR CLINICS

Albert N. Brest, M.D. / Editor-in-Chief

James C. Wilson Professor of Medicine
Director, Division of Cardiology
Jefferson Medical College
Philadelphia, Pennsylvania



F. A. DAVIS COMPANY • Philadelphia

Copyright © 1990 by F. A. Davis Company

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Printed in the United States of America

Last digit indicates print number: 10 9 8 7 6 5 4 3 2 1

Printed on acid-free paper effective with Volume 17, Number 1.

NOTE: As new scientific information becomes available through basic and clinical research, recommended treatments and drug therapies undergo changes. The author(s) and publisher have done everything possible to make this book accurate, up-to-date, and in accord with accepted standards at the time of publication. However, the reader is advised always to check product information (package inserts) for changes and new information regarding dose and contraindications before administering any drug. Caution is especially urged when using new or infrequently ordered drugs.

Library of Congress Cataloging in Publication Data

Cardiovascular clinics. 20/3

Philadelphia, F. A. Davis, 1969-

v. ill. 27 cm.

Editor: v. 1- A. N. Brest

Key title: Cardiovascular clinics, ISSN 0069-0384.

1. Cardiovascular system—Diseases—Collected works. I. Brest, Albert N., ed.

[DNLM: W1 CA77N]

RC681.A1C27 616.1

ISBN 0-8036-3869-8

70-6558

MARC-S

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by F. A. Davis Company for users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the fee of \$.10 per copy is paid directly to CCC, 27 Congress St., Salem, MA 01970. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is: 0361-8477/89 0 + \$.10.

Preface

Identification of *factors of risk*, as originally termed by Kannel and his colleagues in the Framingham Study¹ has taught us much about the pathogenesis and natural history of coronary artery disease and the means to reverse the major cause of disability and death in this country—the morbidity and mortality associated with the cardiovascular diseases. Indeed, since that publication, epidemiologists and clinical investigators concerned with other areas of disease have employed the concept of *risk factors* for other diseases, syndromes, and for the goals of mass public health treatment programs.

In this regard, we have learned of cardiovascular risk factors, coronary heart disease risk factors, hypertension risk factors, renal disease risk factors, risk factors predisposing the individual to neoplastic diseases, and so forth. But the one area with the most thorough and reproducible studies that has resulted in a precise elucidation of specific factors that confer increased risk of enhanced morbidity and mortality, has related to *coronary heart disease*. Other diseases have received less precise delineation of risk factors.

This book details the risk factors underlying coronary heart disease. Some of these factors were identified early on by the Framingham team, others were identified later; but each factor that is discussed here confers significant and independent risk to the morbidity and mortality that result from the atherosclerotic disease process that culminates in coronary heart disease.

Over the past four decades we have witnessed the emergence of amazingly sophisticated means for cardiovascular diagnosis and therapy. As a result of profound advances we have seen a dramatic reduction in cardiovascular morbidity and mortality. For the first time, cardiovascular deaths have been reduced to the extent that they no longer exceed the sum of deaths from all other causes in the United States.

The vast impact of this on the public health is comparable to that of the introduction of antibiotics and their effects on previously lethal diseases. With the advent of penicillin we have seen the amazing near-disappearance of rheumatic fever and its sequelae, rheumatic carditis and valvular heart disease, of luetic heart disease and aneurysms, and of the various forms of endocarditis, myocarditis, and pericarditis.

During this same span of years we have witnessed the remarkable development of an array of technological achievements that include the means for invasive diagnostic procedures such as cardiac catheterization, and noninvasive methods of echocardiography, Doppler studies, and magnetic, radioisotopic, and positron imagery that provides detailed diagnostic and even prognostic information. These innovations, along with extracorporeal means for perfusion, blood banking, and synthetic grafts also have permitted surgical interventions that would not have been conceived at the outset of this cardiovascular odyssey.

Another major advance has been the appearance of new pharmacological modalities: the diuretics, the beta-adrenergic receptor and angiotensin converting enzyme inhibitors, the calcium antagonists and other antihypertensive agents, a spectrum of antiarrhythmic compounds, anticoagulants and fibrinolytic therapy, and the promise of still more innovative and novel modes of therapy that will appear via genetic engineering and other wizardry of the pharmaceutical chemists and molecular biologists.

During these years of highly productive clinical investigation, there has been a parallel series of contributions from our colleagues in the area of cardiovascular epidemiology. These advances have included the demonstration of validity and efficacy of various therapeutic programs by the unique development of complex multicenter trials.

Underlying these areas of clinical achievements have been important long-term population-based studies. The crowning epidemiological achievement has been the Framingham Heart Study and its ability to identify the specific *factors of risk*; by the power of biostatistical analysis, specific risk factors that impart independent risk of premature cardiovascular morbidity and mortality were identified. Some of these factors clearly are not modifiable—advancing years, male gender, and black race. Others are at least partially modifiable—predisposition to diabetes mellitus, increasing body mass, and hyperuricemia. By virtue of the important aforementioned multicenter intervention trials, we have unimpeachable evidence that cigarette consumption, rising systolic and diastolic arterial pressures, hyperlipidemia, diabetes mellitus, and possibly even left ventricular hypertrophy are modifiable, and their correction should reduce morbidity and mortality associated with cardiovascular illnesses.

This is the message of the relatively new era of preventive cardiology—and of this monograph. However, rather than to repeat all of the exciting breakthroughs that have occurred over recent decades, we have chosen areas in which new concepts are being introduced. To be sure, some of these messages concern many of the established risk factors, but their lessons are abundantly clear: correction of each of these factors will improve cardiovascular and overall health. These are the concerns of preventive cardiology as it carries its discipline into the 1990s. Its teachings must certainly be transferred to the everyday practice of cardiovascular medicine for the public health to be improved. This is the challenge to today's cardiovascular physician.

Edward D. Frohlich, M.D.

I. Kannel, WB, Dawber, TR, Kagan, A, et al: Factors of risk in the development of coronary heart disease: Six years' follow-up experience. *Ann Intern Med* 55:33, 1961.

Editor's Commentary

No aspect of cardiology is more important than prevention. Of particular importance is prevention of atherosclerotic coronary disease, which is the leading cause of mortality in the Western world. Attention to contributory factors can curb the development of coronary disease, and, in addition, can benefit general health. This volume of *CARDIOVASCULAR CLINICS* not only explores the classic risk factors such as lipids, hypertension, and smoking, but also examines numerous other topics of special interest such as the reversibility of atherosclerosis, preventive cardiology in the young, prevention of sudden cardiac death, isolated systolic hypertension in the elderly, psychosocial factors in coronary disease, and the risk of left ventricular hypertrophy. Thus, this book should amply serve the interests of a broad audience. I am very grateful to Edward Frohlich for his guidance in the development of this material, and we are both deeply indebted to the contributing authors for their superb contributions.

Albert N. Brest, M.D.
Editor-in-Chief

Contributors

Roger T. Anderson, B.A.

Behavioral Medicine Branch

Division of Epidemiology and Clinical Applications

National Heart, Lung, and Blood Institute

Bethesda, Maryland

Mark L. Armstrong, M.D.

Professor of Medicine

Division of Cardiovascular Diseases

University of Iowa College of Medicine

Iowa City, Iowa

Gerald S. Berenson, M.D.

Professor of Medicine

Department of Medicine

Chief, Division of Cardiology

Louisiana State University

New Orleans, Louisiana

Ann E. Bowler, M.S.

Epidemiologic Consultant

National High Blood Pressure Education Program

National Heart, Lung, and Blood Institute

Bethesda, Maryland

W. Virgil Brown, M.D.

President and CEO

Medlantic Research Foundation

Washington, DC

Jerome D. Cohen, M.D.

Professor of Medicine

Director of Preventive Cardiology Programs

*St. Louis University School of Medicine
St. Louis, Missouri*

Susan M. Czajkowski, Ph.D.
*Behavioral Medicine Branch
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Bethesda, Maryland*

Francis G. Dunn, M.B., Ch.B., F.R.C.P.
*Consultant Cardiologist
Department of Cardiology
Stobhill General Hospital
Honorary Lecturer in Cardiology
University of Glasgow
Glasgow, Scotland*

Edward D. Frohlich, M.D.
*Alton Ochsner Distinguished Scientist
Vice President for Academic Affairs
Alton Ochsner Medical Foundation
New Orleans, Louisiana*

Curt D. Furberg, M.D., Ph.D.
*Professor of Medicine and Chairman
Department of Public Health Sciences
Bowman Gray School of Medicine
Winston-Salem, North Carolina*

Edward Genton, M.D.
*Ochsner Clinic
New Orleans, Louisiana*

David G. Harrison, M.D., Ph.D.
*Associate Professor of Medicine
University of Iowa College of Medicine
Iowa City, Iowa*

David Heber, M.D., Ph.D.
*Associate Clinical Professor of Medicine
Chief, Division of Clinical Nutrition
Department of Medicine
University of California Los Angeles
Los Angeles, California*

Donald D. Heistad, M.D.
*Professor of Internal Medicine and Pharmacology
University of Iowa College of Medicine
Iowa City, Iowa*

Wm. James Howard, M.D.
Director of Clinical Research
Medlantic Research Foundation
Washington, D.C.

Leonard G. Hudzinski, Ph.D.
Director, Ochsner Center for the Elimination of Smoking
Ochsner Medical Institutions
New Orleans, Louisiana

Carolyn C. Johnson, M.S., N.C.C.
Instructor, Department of Medicine
Louisiana State University Medical Center
New Orleans, Louisiana

J. Antonio G. Lopez, M.D.
Fellow Associate
Division of Cardiovascular Diseases
University of Iowa College of Medicine
Iowa City, Iowa

Morton H. Maxwell, M.D.
Clinical Professor of Medicine and Co-Director of Division of Clinical Nutrition
University of California Los Angeles School of Medicine
Los Angeles, California

Marjorie B. Megan
Research Associate
Division of Cardiovascular Diseases
University of Iowa College of Medicine
Iowa City, Iowa

Theresa S. Nicklas, L.D.N., Dr.P.H.
Assistant Professor of Medicine
Department of Medicine
Louisiana State University Medical Center
New Orleans, Louisiana

Margaret C. Oalmann, Dr.P.H.
Professor, Department of Pathology
Louisiana State University School of Medicine
New Orleans, Louisiana

Jeffrey L. Probstfield, M.D.
Scientific Project Officer
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Clinical Trials Branch
Bethesda, Maryland

Edward J. Roccella, Ph.D., M.P.H.

*Coordinator, National High Blood Pressure Education Program
Office of Prevention, Education and Control
National Heart, Lung, and Blood Institute
Bethesda, Maryland*

Henry B. Sadlo, M.D.

*Department of Medicine (Cardiology)
Emory University School of Medicine
Atlanta, Georgia*

Sally A. Shumaker, Ph.D.

*Behavioral Medicine Branch
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Bethesda, Maryland*

Joseph Stokes III, M.D. (deceased)

*Boston University School of Medicine
Boston, Massachusetts*

Jack P. Strong, M.D.

*Boyd Professor and Head
Department of Pathology
Louisiana State University School of Medicine
New Orleans, Louisiana*

Sathanur R. Srinivasan, Ph.D.

*Professor, Department of Medicine and Biochemistry
Louisiana State University Medical Center
New Orleans, Louisiana*

Stephen M. Weiss, Ph.D.

*Chief, Behavioral Medicine
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Bethesda, Maryland*

Nanette K. Wenger, M.D.

*Professor of Medicine (Cardiology)
Emory University School of Medicine
Director, Cardiac Clinics
Grady Memorial Hospital
Atlanta, Georgia*

Mark D. Wittry, M.D.

*St. Louis University School of Medicine
St. Louis, Missouri*

Contents

Part I

CARDIOVASCULAR RISKS: LESSONS FROM THE COMMUNITY

1

1	Cardiovascular Risk Factors	3
	<i>Joseph Stokes III, M.D.</i>	
	Definitions	3
	Characteristics of Risk	3
	Criteria for Causation	4
	Conceptual Model	4
	The Important Risk Factors for Cardiovascular Disease	5
	Genetic Factors	5
	Environmental Factors	6
	Behavioral Factors	7
	Diet	7
	Physical Activity	8
	Cigarette Smoking	8
	Alcohol Use	10
	Stress and Type A/B Behavior	10
	Other Relevant Behaviors	11
	Atherogenic Traits	11
	Dyslipidemia	11
	Hypertension	13
	Glucose Intolerance	14
	Obesity	14
	Hematologic/Rheologic Factors	15
	Other Traits	15
	Risk Profiles of Atherogenic Disease	16
	Secular Trends	16
	Clinical Methods of Risk Assessment	16

2	Prevention of Adult Heart Disease Beginning in the Pediatric Age	21
	<i>Gerald S. Berenson, M.D., Sathanur R. Srinivasan, Ph.D., Theresa A. Nicklas, L.D.N., Dr.P.H., and Carolyn C. Johnson, M.S., N.C.C.</i>	
	Validation of Cardiovascular Risk Factors in Children	22
	Lipoproteins in Children and Adolescents	23
	Levels at Birth and Changes Through Adolescence	25
	Body Habitus	26
	Familial Aggregation	27
	Life-style and Behavior	28
	Dietary Influence	29
	Eating Patterns of American Children	30
	Infants	30
	Preschoolers	30
	School-Aged Children	31
	Food Sources of Dietary Components	33
	Dietary Guidelines	34
	Recommendations Before Age Two	34
	Recommendations After Age Two	34
	Practical Application of Dietary Recommendations	35
	Role of the Food Industry	37
	Behavioral Approaches to Beginning Prevention	38
	Strategies for Preventive Cardiology in	
	Pediatrics—Heart Smart Program	39
	Population Strategy—Program for School Children	39
	High Risk Strategy—Family Health Promotion	40
Part 2		
	CARDIOVASCULAR RISK FACTORS: BLOOD PRESSURE, BLOOD VESSELS, AND THE HEART	47
3	Hypertension as a Risk Factor	49
	<i>Edward J. Roccella, Ph.D., M.P.H., and Ann E. Bowler, M.S.</i>	
	Measuring Risk	49
	Establishing Risk Factor Causality	51
	Strength, Consistency, and Dose-Response of the Data	51
	Timing	55
	Biological Plausibility	55
	Specificity	55
	Replication	56
	Reversing the Risk	57
	Risk and the Implications for High Blood Pressure Control Programs	60
4	Systolic Hypertension in the Elderly: Controlled or Uncontrolled	65
	<i>Jeffrey L. Probstfield, M.D., and Curt D. Furberg, M.D., Ph.D.</i>	
	Prevalence	66
	Etiology and Pathophysiology	67

Risk Implications	68
Systolic Versus Diastolic Blood Pressure	68
What Is the Risk of an Increased Systolic Pressure?	69
Can Isolated Systolic Hypertension Be Controlled?	71
Detection and Evaluation	72
Nonpharmacologic Approach to Therapy	73
Pharmacologic Approach to Therapy	73
Should Isolated Systolic Hypertension Be Treated?	76
SHEP Pilot	76
SHEP Main Trial	77
What Treatment While We Wait for SHEP?	78
Adverse Reactions to Drug Therapy	80
Specific Recommendations	80
 5 Left Ventricular Hypertrophy: An Independent Factor of Risk	 85
<i>Edward D. Frohlich, M.D.</i>	
Cardiovascular Risk Factors	85
Left Ventricular Hypertrophy	86
Development	86
Nonhemodynamic Factors	87
LVH: Potential Mechanisms of Risk	87
Regression of LVH	89
"Reversal" of LVH	89
"Reversal" of Risk	91
 6 Prevention of Sudden Cardiac Death	 95
<i>Francis G. Dunn, M.B., Ch.B., F.R.C.P.</i>	
Risk Factors for Sudden Cardiac Death and Their Mechanisms	96
Coronary Artery Disease	96
Risk Factor	96
Mechanisms	96
Left Ventricular Hypertrophy in Patients with	
Hypertension	97
Risk Factor	97
Mechanisms	97
Cardiomyopathies	98
Conduction Abnormalities	99
Biochemical Abnormalities	99
Additional Factors	99
Usefulness of Cardiac Studies as Markers for Sudden Cardiac	
Death	100
Electrocardiogram	100
Chest X-Ray	100
Exercise Testing	101
Ambulatory ECG Testing	101
Echocardiography	102
Coronary Arteriography	102
Strategy for Prevention	102

Prevention in High Risk Groups	103
Survivors of Sudden Cardiac Death	103
Post-Myocardial Infarction	104
Hypertrophic Obstructive Cardiomyopathy	104
Wolff-Parkinson-White Syndrome	104
QT Prolongation	105
Hypertensive LVH	105
Left Ventricular Dysfunction	105
Prevention in the General Population	105
Cardiopulmonary Resuscitation (CPR)	105
Impact of Cardiovascular Risk Factor Assessment	106

Part 3

REVERSIBILITY AND PLATELETS 111

7 Reversibility of Atherosclerosis 113

*Mark L. Armstrong, M.D., Donald D. Heistad, M.D.,
Marjorie B. Megan, J. Antonio G. Lopez, M.D., and
David G. Harrison, M.D., Ph.D.*

Evaluating the Extent of Atherosclerosis 114

Pathologic Observations 114

Arteriographic Studies 115

Physiologic Improvement 116

Lessons from Animal Models of Atherosclerosis and 116

Regression 116

Plaque Components and Their Potential for Regression 117

Endothelium 117

Intimal Cells 117

Lipid Content 118

Connective Tissue 118

Necrosis and Calcification 120

Neovascularization and Hemorrhage 120

Fibrin and Thrombus 121

Vascular Responses in Atherosclerosis 121

Reversibility as a Central Concept of Therapy 123

8 Modification of Thrombogenic Factors in Cardiac Disease 127

Edward Genton, M.D.

Mechanism of Thrombosis 127

Methods for Prevention or Inhibition of Thrombosis 128

Platelet Inhibitors 128

Aspirin 129

Dipyridamole 129

Anticoagulants 129

Heparin 129

Coumarin Derivatives 129

Thrombosis and Antithrombotic Therapy in Clinical Disorders	130
Valvular Heart Disease	130
Prosthetic Heart Valves	130
Myocardial Abnormalities	131
Acute Myocardial Infarction	131
Cardiomyopathies	131
Coronary Artery Disease	132
Part 4	
BEHAVIORAL INTERVENTIONS FOR THE CARDIOLOGIST	133
9 Psychosocial Factors in Coronary Heart Disease	135
Stephen M. Weiss, Ph.D., Susan M. Czajkowski, Ph.D., Sally A. Shumaker, Ph.D., and Roger T. Anderson, B.A.	
Intrapersonal: Coronary-Prone Behavior and CHD	136
Interpersonal: Social Support and CHD	138
Defining Social Support	138
Epidemiological Studies	139
Limitations of Research on Social Support and CHD	140
Future Directions for Research on Support and CHD	141
Environmental: Occupational Stress and CHD	141
10 Nutritional Treatment of Hyperlipidemia and Obesity	149
Morton H. Maxwell, M.D., and David Heber, M.D., Ph.D.	
Nutritional Treatment of Hyperlipidemia	149
Classifications of Hyperlipidemia	150
Elements of the Diet Affecting Cholesterol	152
Total Fat and Calories	152
Dietary Fat Quality	152
Dietary Cholesterol	152
Dietary Fiber	154
Obesity and Hypercholesterolemia	155
11 Treatment of Lipoprotein Disorders	157
W. Virgil Brown, M.D., and William James Howard, M.D.	
Classification	159
Initial Evaluation	159
Follow-Up	160
Dietary Therapy	161
Changing the Diet	161
Monounsaturated and Polyunsaturated Fats	163
Fish and Fish Oils	164
Fiber	164
Achieving Dietary Compliance	165
Drug Treatment	166
Establishing Goals for Treatment	166

Bile Acid Sequestrants	167
Expected Efficacy	167
Clinical Efficacy	167
Side Effects	167
Contraindications	168
Mechanisms of Action	168
Clinical Use	168
HMG Co-A Reductase Inhibitors	171
Mechanisms of Action	171
Side Effects	172
Combination Therapy	172
Clinical Efficacy	172
Probucol (Lorelco)	172
Lipoprotein Effects	173
Side Effects	173
Patient Adherence to the Therapeutic Regimen	173
 12 The Role of Exercise in the Primary and Secondary Prevention of Coronary Atherosclerotic Heart Disease	 177
Henry B. Sadlo, M.D., and Nanette K. Wenger, M.D.	
The Exercise/Coronary Atherosclerotic Heart Disease Relationship	178
Exercise as a Single Coronary Risk Variable	179
Influence of Exercise on Other Coronary Risk Factors	179
Exercise, Lipids, and Lipoprotein Profiles	179
Exercise and Hypertension	180
Exercise and Smoking Habits	180
Exercise and Diabetes Mellitus	181
Exercise and Coagulation Factors	181
Exercise and Obesity	181
Exercise and Psychological Well-Being	181
Exercise and the Primary Prevention of Coronary Heart Disease	182
Exercise and the Secondary Prevention of Coronary Heart Disease	184
Potential Exercise Risks and Exercise Contraindications in Patients with Coronary Artery Disease	186
Summary: Exercise Recommendations	187
 13 Supervised and Unsupervised Exercise for the General Population and Patients with Known Cardiac Disease	 191
Jerome D. Cohen, M.D., and Mark D. Wutry, M.D.	
Benefits of Exercise	191
Cardiovascular Effects	191
Blood Lipid Effects	193
Effects on Body Weight and Composition	193
Changes in Carbohydrate Metabolism	193
Psychologic Effects	194

Potential Complications of Vigorous Exercise	194
Orthopedic Precautions	194
Cardiovascular Precautions	194
Evaluation Prior to Beginning an Exercise Program	195
Exercise Prescription	197
Warm-Up	198
Aerobic Phase of Exercise	198
Cool-Down	199
Special Considerations for Cardiac Patients	200
14 Effects of Smoking on the Cardiovascular System	205
<i>Jack P. Strong, M.D., and Margaret C. Oalman, Dr.P.H.</i>	
Defining the Problem	206
Coronary Heart Disease	207
Cerebrovascular Disease	210
Atherosclerotic Peripheral Vascular Disease	211
Atherosclerosis	211
Smoking and Aortic Atherosclerosis	213
Smoking and Coronary Atherosclerosis	213
Smoking and Aortic and Coronary Atherosclerosis	215
Smoking and Cerebral Atherosclerosis	216
Possible Mechanisms Relating Tobacco Usage and Atherosclerosis	216
The Effect of Cessation of Cigarette Smoking	216
Intervention Issues	217
15 Modification of the Smoking Habit	223
<i>Leonard G. Hudzinski, Ph.D.</i>	
Effects of Intervention by the Physician	223
Banning Smoking in the Workplace	224
Passive Smoke Inhalation	224
Effects of Tobacco on Prescribed Medications	224
Planning a Smoking Cessation Program for Your Patient	225
Prescribing Nicotine Chewing Gum	227
Smoking Relapse Prevention	228
INDEX	231